Betahistine dihydrochloride
Betahistine dihydrochloride
CLINICAL USE
Treatment of vertigo, tinnitus and hearing loss associated with Ménière’s syndrome
DOSE IN NORMAL RENAL FUNCTION
8–16 mg, 3 times a day
PHARMACOKINETICS
Molecular weight :209.1 %Protein binding :0–5 %Excreted unchanged in urine : 85–90 Volume of distribution (L/kg) :No datahalf-life – normal/ESRD (hrs) :3.4/– DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50 : Dose as in normal renal function 10 to 20 : Dose as in normal renal function <10 : 8–16 mg, 2–3 times a day DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD :Likely dialysability. Dose as in GFR <10 mL/min HD :Likely dialysability. Dose as in GFR <10 mL/minHDF/high flux :Likely dialysability. Dose as in GFR <10 mL/minCAV/VVHD :Likely dialysability. Dose as in GFR 10 to 20 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsNone known ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
Betahistine is rapidly and completely absorbed after oral administrationIt is excreted almost exclusively in the urine as 2-pyridylacetic acid within 24 hours of administration
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home
